{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:37:42Z","timestamp":1791401862206,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106852","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T12:35:33Z","timestamp":1684154133000},"page":"106852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics\/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF)"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-5973","authenticated-orcid":false,"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-3595","authenticated-orcid":false,"given":"Tommaso","family":"Tonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-8635","authenticated-orcid":false,"given":"Paolo","family":"Gaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Siniscalchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106852_bib0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/QCO.0000000000000518","article-title":"Managing Acinetobacter baumannii infections","volume":"32","author":"Garnacho-Montero","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0002","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0003","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/antibiotics10111311","article-title":"Assessment of a PK\/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented gram-negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028019865873","article-title":"Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: An update","volume":"54","author":"Hoff","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106852_bib0007","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-021-01040-y","article-title":"Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics","volume":"60","author":"Gatti","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0008","doi-asserted-by":"crossref","first-page":"ofab252","DOI":"10.1093\/ofid\/ofab252","article-title":"Cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration","volume":"8","author":"Kobic","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0009","doi-asserted-by":"crossref","first-page":"ofac484","DOI":"10.1093\/ofid\/ofac484","article-title":"Pharmacokinetic analysis and in vitro synergy evaluation of cefiderocol, sulbactam, and tigecycline in an extensively drug-resistant Acinetobacter baumannii pneumonia patient receiving continuous venovenous hemodiafiltration","volume":"9","author":"Kobic","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106395","article-title":"Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration","volume":"58","author":"Fratoni","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0011","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/cc13775","article-title":"Ventilator-associated pneumonia in the ICU","volume":"18","author":"Kalanuria","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0012","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12879-019-4604-0","article-title":"Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment","volume":"19","author":"Silva-Nunes","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2021.10.014","article-title":"A descriptive case series of PK\/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and\/or VAP treated with cefiderocol","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0014","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoints for cefiderocol from EUCAST 2023."},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/antibiotics11040458","article-title":"Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/antibiotics12020213","article-title":"Fast and sensitive analysis of cefiderocol in human plasma microsamples by liquid chromatography-isotope dilution tandem mass spectrometry for therapeutic drug monitoring","volume":"12","author":"Barone","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0017","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/antibiotics11121739","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0018","article-title":"Intensity of continuous renal replacement therapy for acute kidney injury","volume":"10","author":"Fayad","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2023.106852_bib0019","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106852_bib0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14787210.2023.2169131","article-title":"Jumping into the future: overcoming pharmacokinetic\/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams","volume":"21","author":"Gatti","year":"2023","journal-title":"Expert Rev Anti-Infect Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:35Z","timestamp":1760377535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001310"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106852","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics\/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106852"}}